Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio @reportablenews

Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company's lead ophthalmic program and establishing a foundation for expansion into additional antiviral indications. The acquisition expands the company's development pipeline beyond ocular...


http://dlvr.it/TRjqRQ

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

ASTRA TT Signs Strategic MOU with India's BIS to Accelerate Green Charging Infrastructure Across the Nation #Publishing #Technology